文献速递白血病

Idasanutlin联合阿糖胞苷治疗复发或难治性急性髓系白血病:MIRROS试验结果

Idasanutlin plus cytarabine in relapsed or refractory acute myeloid leukemia: results of the MIRROS trial.
PubMed 文献 · Blood Adv · 2022-01-01

3期MIRROS试验纳入447例复发/难治性急性髓系白血病成人患者,按2:1随机分配至Idasanutlin 300mg或安慰剂口服每日两次联合阿糖胞苷1g/m²静脉注射第1-5天(28天周期)。主要终点TP53野生型意向治疗人群的总生存期未达到:中位8.3个月 vs 9.1个月,分层HR 1.08(95%CI 0.81-1.45;P=0.58)。完全缓解率20.3% vs 17.1%,总缓解率38.8% vs 22.0%。

要点

  • 在TP53野生型意向治疗人群中,Idasanutlin联合阿糖胞苷较安慰剂联合阿糖胞苷未改善总生存期(中位8.3 vs 9.1个月;HR 1.08;P=0.58)。
  • 完全缓解率在Idasanutlin组为20.3%,安慰剂组为17.1%(OR 1.23;95%CI 0.70-2.18)。
  • 总缓解率在Idasanutlin组为38.8%,安慰剂组为22.0%(OR 2.25;95%CI 1.36-3.72)。

核心结论

  • 尽管总缓解率提高,但在复发/难治性急性髓系白血病患者中,阿糖胞苷联合Idasanutlin未改善总生存期或完全缓解率。

研究设计与样本

  • 3期MIRROS试验(NCT02545283)纳入447例复发/难治性急性髓系白血病成人患者,按2:1随机分配至Idasanutlin 300mg或安慰剂口服每日两次联合阿糖胞苷1g/m²静脉注射第1-5天(28天周期)。
  • 入选标准为经≤2线既往诱导方案初始治疗后或挽救化疗方案后复发或难治,东部肿瘤协作组体能状态≤2,不论TP53突变状态。
  • 主要分析(数据截止2019年11月)时入组436例,其中TP53野生型意向治疗人群355例。

主要发现

  • 主要终点TP53野生型意向治疗人群的总生存期未达到:Idasanutlin联合阿糖胞苷组中位8.3个月 vs 安慰剂联合阿糖胞苷组9.1个月(分层HR 1.08;95%CI 0.81-1.45;P=0.58)。
  • 完全缓解率在Idasanutlin联合阿糖胞苷组为20.3%,安慰剂联合阿糖胞苷组为17.1%(OR 1.23;95%CI 0.70-2.18)。
  • 总缓解率在Idasanutlin联合阿糖胞苷组为38.8%,安慰剂联合阿糖胞苷组为22.0%(OR 2.25;95%CI 1.36-3.72)。
  • 常见任何级别不良事件(任一组发生率≥10%)包括腹泻(87.0% vs 32.9%)、发热性中性粒细胞减少(52.8% vs 49.3%)和恶心(52.5% vs 31.5%)。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

The phase 3 MIRROS (MDM2 antagonist Idasanutlin in Relapsed or Refractory acute myeloid leukemia [AML] for Overall Survival) trial (NCT02545283) evaluated the efficacy and safety of the small-molecule MDM2 antagonist idasanutlin plus cytarabine in patients with relapsed/refractory (R/R) AML. Adults (n = 447) with R/R AML whose disease relapsed or was refractory after ≤2 prior induction regimens as initial treatment or following salvage chemotherapy regimen, with Eastern Cooperative Oncology Group performance status ≤2 were enrolled regardless of TP53 mutation status and randomly assigned 2:1 to idasanutlin 300 mg or placebo orally twice daily plus cytarabine 1 g/m2 IV on days 1 to 5 of 28-day cycles. At primary analysis (cutoff, November 2019), 436 patients were enrolled, including 355 in the TP53 wild-type intention-to-treat (TP53WT-ITT) population. The primary endpoint, overall survival in the TP53WT-ITT population, was not met (median, 8.3 vs 9.1 months with idasanutlin-cytarabine vs placebo-cytarabine; stratified hazard ratio [HR], 1.08; 95% confidence interval [CI], 0.81-1.45; P = .58). The complete remission (CR) rate, a key secondary endpoint, was 20.3% vs 17.1% (odds ratio [OR], 1.23; 95% CI, 0.70-2.18). The overall response rate (ORR) was 38.8% vs 22.0% (OR, 2.25; 95% CI, 1.36-3.72). Common any-grade adverse events (≥10% incidence in any arm) were diarrhea (87.0% vs 32.9%), febrile neutropenia (52.8% vs 49.3%), and nausea (52.5% vs 31.5%). In summary, despite improved ORR, adding idasanutlin to cytarabine did not improve overall survival or CR rates in patients with R/R AML.

来源:Blood Adv,查看原文。版权归原作者所有。

引用

  1. Konopleva MY, Röllig C, Cavenagh J, et al. Idasanutlin plus cytarabine in relapsed or refractory acute myeloid leukemia: results of the MIRROS trial. Blood Adv. 2022. PMID: 35413116. doi:10.1182/bloodadvances.2021006303

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。